Results
Between 2 October 2017, and 16 July 2020, 397 patients were enrolled from 65 institutions: 197 patients in the FTD/TPI plus bevacizumab group (1 patient was excluded owing to incomplete informed consent), and 199 patients in the control group were included in the FAS (Fig. 